Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study

被引:14
|
作者
Valenzuela-Vallejo, Laura [1 ]
Chrysafi, Pavlina [1 ]
Kouvari, Matina [1 ]
Guatibonza-Garcia, Valentina [1 ]
Mylonakis, Sophia C. [1 ]
Katsarou, Angeliki [1 ]
Verrastro, Ornella [2 ]
Markakis, Georgios [3 ]
Eslam, Mohammed [4 ,5 ]
Papatheodoridis, Georgios [3 ]
Mingrone, Geltrude [2 ]
George, Jacob [4 ,5 ,7 ]
Mantzoros, Christos S. [6 ]
机构
[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
[2] Univ Cattolica Sacro Cuore, Dept Gastroenterol, Rome, Italy
[3] Natl & Kapodistrian Univ Athens, Gen Hosp Athens Laiko, Med Sch, Dept Gastroenterol, Athens, Greece
[4] Westmead Hosp, Storr Liver Ctr, Westmead Inst Med Res, Sydney, NSW, Australia
[5] Univ Sydney, Sydney, NSW, Australia
[6] Boston VA Healthcare Syst, Dept Med, Boston, MA 02130 USA
[7] Westmead Hosp, Westmead Inst Med Res, Sydney Med Sch, Sydney West Local Hlth Dist, 176 Hawkesbury Rd, Westmead, NSW 2145, Australia
来源
关键词
Metabolic dysfunction associated fatty liver disease (MASLD); Metabolic dysfunction associated steatohepatitis (MASH); Non-alcoholic fatty liver disease (NAFLD); Non-alcoholic steatohepatitis (NASH); Metabolic-associated fatty liver disease (MAFLD); Fatty liver disease (FLD); Obesity; Diabetes; ACTIVIN-A; HEPATIC STEATOSIS; SCORING SYSTEM; ADIPONECTIN; LEPTIN; ASSOCIATION; FOLLISTATIN; VALIDATION; RISK; GH;
D O I
10.1016/j.metabol.2023.155694
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The role of metabolic/inflammatory hormonal systems in metabolic dysfunction associated steatotic liver disease (MASLD) remains to be fully elucidated.Purpose: To report the levels of the novel total and H-specific growth differentiation factor-15 (GDF-15) and other established hormonal systems and to describe hormonal patterns in controls and patients with MASLD and its stages.Methods: This is a multicenter study from two Gastroenterology-Hepatology Departments (Greece and Australia) and one Bariatric-Metabolic Surgery Department (Italy). Overall, n = 455 serum samples of patients with biopsy -proven MASLD (n = 374) and Controls (n = 81) were recruited.Results: We report for the first time that total and H-specific GDF-15 levels are higher in MASLD, at-risk metabolic dysfunction associated steatohepatitis (MASH), and severe fibrosis than in Controls. In addition, follistatin-like-3 (FSTL-3), free insulin-like growth factor-1 (IGF-1), leptin, and insulin levels were higher in MASLD patients than in Controls, while adiponectin levels were lower in MASLD subjects than in Controls. Activin-A, follistatin (FST), FSTL-3, and insulin levels significantly increased in severe fibrosis compared to no/mild fibrosis, while free IGF-1 decreased. In addition, adiponectin levels were lower in subjects without fibrosis vs. any fibrosis. Moreover, GDF-15 presented a strong positive association for the likelihood of having MASLD and at-risk MASH, while in adjusted analyses, FST and adiponectin showed inverse associations. Two different patterns of at-risk MASH were revealed through unsupervised analysis (total variation explained=54%). The most frequent pattern met in our sample (34.3%) was characterized by higher levels of total and H-specific GDF-15, follistatins, and activins, as well as low adiponectin levels. The second pattern revealed was characterized by high levels of free IGF-1, in-sulin, and leptin, with low levels of activin-A and adiponectin. Similar patterns were also generated in the case of overall MASLD.Conclusions: Total and H-specific GDF-15 levels increase as MASLD severity progresses. FSTL-3, free IGF-1, leptin, and insulin are also higher, whereas adiponectin and activin-A levels are lower in the MASLD group than in Controls. Hormonal systems, including GDF-15, may not only be involved in the pathophysiology but could also prove useful for the diagnostic workup of MASLD and its stages and may potentially be of therapeutic value.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] THE HISTOLOGICAL CHARACTERISTICS OF PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS
    Fu, Yi-Ming
    Ji, Dong
    Lau, George K. K.
    Chen, Guo-Feng
    HEPATOLOGY, 2019, 70 : 1075A - 1076A
  • [22] Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis
    Aminian, Ali
    Al-Kurd, Abbas
    Wilson, Rickesha
    Bena, James
    Fayazzadeh, Hana
    Singh, Tavankit
    Albaugh, Vance L.
    Shariff, Faiz U.
    Rodriguez, Noe A.
    Jin, Jian
    Brethauer, Stacy A.
    Dasarathy, Srinivasan
    Alkhouri, Naim
    Schauer, Philip R.
    McCullough, Arthur J.
    Nissen, Steven E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (20): : 2031 - 2042
  • [23] LIVER STIFFNESS BY TRANSIENT ELASTOGRAPHY TO PREDICT CLINICAL EVENTS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: A MULTICENTER STUDY OF 995 BIOPSY-PROVEN CASES.
    Nakatsuka, Takuma
    Tateishi, Ryosuke
    Takahashi, Hirokazu
    Eguchi, Yuichiro
    Murakami, Eisuke
    Chayama, Kazuaki
    Okanoue, Takeshi
    Koike, Kazuhiko
    HEPATOLOGY, 2022, 76 : S81 - S82
  • [24] Biopsy-Proven Pulmonary Determinants of Heart Disease
    Felipe Muniz de Castro Zampieri
    Edwin Roger Parra
    Mauro Canzian
    Leila Antonângelo
    Bráulio Luna Filho
    Carlos Roberto Ribeiro de Carvalho
    Ronaldo Adib Kairalla
    Vera Luiza Capelozzi
    Lung, 2010, 188 : 63 - 70
  • [25] THE PREVALENCE OF BIOPSY-PROVEN GLOMERULAR DISEASE IN QUEENSLAND
    Jegatheesan, D.
    Nath, K.
    Liyanage, T.
    Francis, L.
    John, G.
    Ranganathan, D.
    NEPHROLOGY, 2011, 16 : 82 - 82
  • [26] Biopsy-Proven Pulmonary Determinants of Heart Disease
    de Castro Zampieri, Felipe Muniz
    Parra, Edwin Roger
    Canzian, Mauro
    Antonangelo, Leila
    Luna Filho, Braulio
    Ribeiro de Carvalho, Carlos Roberto
    Kairalla, Ronaldo Adib
    Capelozzi, Vera Luiza
    LUNG, 2010, 188 (01) : 63 - 70
  • [27] Cardiovascular Outcomes in Patients With Biopsy-proven Alcohol-related Liver Disease
    Hagstrom, Hannes
    Thiele, Maja
    Sharma, Rajani
    Simon, Tracey G.
    Roelstraete, Bjorn
    Soderling, Jonas
    Sundstrom, Johan
    Ludvigsson, Jonas F.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (07) : 1841 - +
  • [28] Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease
    Alsaif, Faisal A.
    Alqahtani, Sara H.
    Alsadoon, Amani M.
    Alswat, Khalid A.
    Abdo, Ayman A.
    Hassanain, Mazen M.
    Alsharabi, Abdulsalam B.
    Aljuhani, Ghadeer R.
    Alkhalidi, Hisham M.
    Elsharkawy, Mohammad S.
    Alotaibi, Maram A.
    Sanai, Faisal M.
    Al-hamoudi, Waleed K.
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2020, 26 (04): : 204 - 209
  • [29] NATURAL-KILLER ACTIVITY IN PATIENTS WITH BIOPSY-PROVEN LIVER-DISEASE
    SERDENGECTI, S
    JONES, DB
    HOLDSTOCK, G
    WRIGHT, R
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1981, 45 (02): : 361 - 364
  • [30] Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
    Ampuero, Javier
    Aller, Rocio
    Gallego-Duran, Rocio
    Crespo, Javier
    Abad, Javier
    Gonzalez-Rodriguez, Agueda
    Gomez-Camarero, Judith
    Caballeria, Joan
    Lo Iacono, Oreste
    Ibanez, Luis
    Garcia-Samaniego, Javier
    Martin-Mateos, Rosa
    Frances, Ruben
    Fernandez-Rodriguez, Conrado
    Diago, Moises
    Soriano, German
    Andrade, Raul J.
    Latorre, Raquel
    Jorquera, Francisco
    Morillas, Rosa M.
    Escudero, Desam
    Estevez, Pamela
    Hernandez-Guerra, Manuel
    Augustin, Salvador
    Pareja-Megia, Maria Jesus
    Banales, Jesus M.
    Aspichueta, Patricia
    Benlloch, Salvador
    Rosales, Jose Miguel
    Salmeron, Javier
    Turnes, Juan
    Romero-Gomez, Manuel
    LIVER INTERNATIONAL, 2021, 41 (09) : 2076 - 2086